You are now leaving Mitsubishi Tanabe Pharma Canada and visiting a third-party website.

If you are interested in exploring careers at MTP-CA, please email
contact@mt-pharma-canada.com.

Media Center

Background Image

Press Releases

  • Mitsubishi Tanabe Pharma Canada Announces New Leadership

    Mitsubishi Tanabe Pharma Canada Announces...

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)

    TORONTO, ON August 15, 2022 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program

    TORONTO, March 10, 2021 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary

    TORONTO, August 19, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

    TORONTO, October 4, 2018 -- Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension

    TORONTO, Canada – March 30, 2023 –...

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS

    (MTPA) is pleased to announce a positive...

    Read More
  • Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

    TORONTO, Canada - May 13, 2022 –...

    Read More
  • MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, July 7, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

    TORONTO, June 18, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

    TORONTO, September 28, 2018 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS

    Comprehensive clinical development program...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

    TORONTO, November 23, 2021 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada

    TORONTO, September 21, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • Update on Canadian Product Availability

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces New Leadership

    Mitsubishi Tanabe Pharma Canada Announces...

    Read More
  • Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension

    TORONTO, Canada – March 30, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS

    (MTPA) is pleased to announce a positive...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS

    Comprehensive clinical development program...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)

    TORONTO, ON August 15, 2022 – Mitsubishi...

    Read More
  • Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

    TORONTO, Canada - May 13, 2022 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

    TORONTO, November 23, 2021 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program

    TORONTO, March 10, 2021 - Mitsubishi...

    Read More
  • MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada

    TORONTO, September 21, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary

    TORONTO, August 19, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, July 7, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

    TORONTO, June 18, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Update on Canadian Product Availability

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

    TORONTO, October 4, 2018 -- Mitsubishi...

    Read More
  • New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

    TORONTO, September 28, 2018 – Mitsubishi...

    Read More